Amphastar Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Amphastar Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 95.1 times by its yearly operating cash. Higher than 97% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 34% of its market value (net debt). Lower than 89% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.8 times. Higher than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$140Over the last 3 years, every $100 of reported profit came with $140 of operating cash.
Lower than 55% of Healthcare companies in United States.
Self-Funding Ratio
4.8×Over the last 3 years its own operating cash covered its investment spending (capex) 4.8 times.
Higher than 86% of Healthcare companies in United States.
Cash Locked Ratio
$42For every $100 of sales, $42 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $34 tied up three years earlier.
More money tied up than 85% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$3Sales grew 44% in 3 years; of every extra $100 of sales, $3 became extra profit.
Lower than 64% of Healthcare companies in United States.
Asset Productivity Ratio
+44% / +120%In 3 years sales changed by +44% while total assets changed by +120%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
95.1×Debt due within a year is covered 95.1 times by its yearly operating cash.
Higher than 97% of Healthcare companies in United States.
Cash Cushion Ratio
−34%Debt, after subtracting cash, equals 34% of its market value (net debt).
Lower than 89% of Healthcare companies in United States.
Tangible Assets Ratio
65%Of every $100 the company owns, $65 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
28%Of every $100 of net worth, $28 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 62% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Amphastar Pharmaceuticals, Inc. owes $0.56 for every $1 it owns. Net profit fell 39% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
15.4Investors pay $15.4 for every $1 of Amphastar Pharmaceuticals, Inc.'s yearly profit, lower than 74% of Healthcare companies in United States.
P/B ratio
1.44The share price is 1.44 times Amphastar Pharmaceuticals, Inc.'s book value per share, lower than 69% of Healthcare companies in United States.
Market cap
$1.1 BThe total market value of all of Amphastar Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$768 MWhat Amphastar Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$18.06Net worth divided by the number of shares. The share price of $26.04 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
10.3%Amphastar Pharmaceuticals, Inc. earned 10.3% on its shareholders' money over the last year, higher than 84% of Healthcare companies in United States.
Owes vs Owns
0.56×Amphastar Pharmaceuticals, Inc. owes $0.56 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Dividend yield
NoneAmphastar Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
-2%Revenue fell 2% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Profit growth
-39%Net profit fell 39% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Profit margin
13.6%Amphastar Pharmaceuticals, Inc. keeps $14 of every $100 of revenue as net profit.
Cash quality
1.6×Cash from Amphastar Pharmaceuticals, Inc.'s business was 1.6× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
5.5×Amphastar Pharmaceuticals, Inc.'s operating profit covered its interest costs 5.5 times in the year to Dec 2025.
Cash vs debt
Net debtAmphastar Pharmaceuticals, Inc. had $373 M more debt than cash (net debt) at Dec 2025.
Questions
What is Amphastar Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $15.4 for every $1 of Amphastar Pharmaceuticals, Inc.'s yearly profit, lower than 74% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Amphastar Pharmaceuticals, Inc.: $1.1 B ÷ $768 M (30 Jun 2026) = 1.4.
What is Amphastar Pharmaceuticals, Inc.'s return on equity?
Amphastar Pharmaceuticals, Inc. earned 10.3% on its shareholders' money over the last year, higher than 84% of Healthcare companies in United States.
How much does Amphastar Pharmaceuticals, Inc. owe compared with what it owns?
Amphastar Pharmaceuticals, Inc. owes $0.56 for every $1 it owns (moderate), higher than 61% of Healthcare companies in United States.
Does Amphastar Pharmaceuticals, Inc. pay a dividend?
No. Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.
Is Amphastar Pharmaceuticals, Inc.'s revenue growing?
Revenue fell 2% in the year to Dec 2025, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.